<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39346556</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>An exploratory analysis of associations of genetic variation with the efficacy of tocilizumab in severe COVID-19 patients. A pharmacogenetic study based on next-generation sequencing.</ArticleTitle><Pagination><StartPage>1426826</StartPage><MedlinePgn>1426826</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1426826</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2024.1426826</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">In the context of the cytokine storm the takes place in severe COVID-19 patients, the <i>Interleukin 6</i> (<i>IL6</i>) pathway emerges as one of the key pathways involved in the pathogenesis of this hyperinflammatory state. The strategy of blocking the inflammatory storm by targeting the <i>IL6</i> is a promising therapy to mitigate mortality. The use of Tocilizumab was recommended by the World Health Organization (WHO) to treat severe COVID-19 patients. However, the efficacy of Tocilizumab is variable. We hypothesize that the genetic background could be behind the efficacy of Tocilizumab in terms of mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a targeted-next generation sequencing of 287 genes, of which 264 belong to a community panel of ThermoFisher for the study of genetic causes of primary immunodeficiency disorders, and 23 additional genes mostly related to inflammation, not included in the original community panel. This panel was sequenced in an initial cohort of 425 COVID-19 patients, of which 232 were treated with Tocilizumab and standard therapy, and 193 with standard therapy only. Selected genetic variants were genotyped by single base extension in additional 245 patients (95 treated with Tocilizumab and 150 non-treated with Tocilizumab). Appropriate statistical analyses and internal validation, including logistic regression models, with the interaction between Tocilizumab and genetic variants, were applied to assess the impact of these genetic variants in the efficacy of Tocilizumab in terms of mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Age (<i>p</i> &lt; 0.001) and cardiovascular disease (<i>p</i> &lt; 0.001) are risk factors for mortality in COVID-19 patients. The presence of GG and TT genotypes at <i>IL10Rβ</i> (rs2834167) and <i>IL1β</i> (rs1143633) genes significantly associates with a reduced risk of mortality in patients treated with Tocilizumab (OR = 0.111; 95%CI = 0.015-0.829; <i>p</i> = 0.010 and OR = 0.378; 95%CI = 0.154-0.924; <i>p</i> = 0.028 respectively). The presence of CC genotype at <i>IL1RN</i> (rs2234679) significantly associates with an increased risk of mortality, but only in patients not treated with Tocilizumab (OR = 3.200; 95%CI = 1.512-6.771; <i>p</i> = 0.002). Exhaustive internal validation using a bootstrap method (B = 500 replicates) validated the accuracy of the predictive models.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">We developed a series of predictive models based on three genotypes in genes with a strong implication in the etiopathogenesis of COVID-19 disease capable of predicting the risk of mortality in patients treated with Tocilizumab.</AbstractText><CopyrightInformation>Copyright © 2024 Durán-Sotuela, Vázquez-García, Relaño-Fernández, Balboa-Barreiro, Fernández-Tajes, Blanco and Rego-Pérez.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durán-Sotuela</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC) Sergas, Universidade da Coruña (UDC), A Coruña, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vázquez-García</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC) Sergas, Universidade da Coruña (UDC), A Coruña, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Relaño-Fernández</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC) Sergas, Universidade da Coruña (UDC), A Coruña, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balboa-Barreiro</LastName><ForeName>Vanesa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Unidad de Apoyo a La Investigación, Grupo de Investigación en Enfermería y Cuidados en Salud, Grupo de Investigación en Reumatología y Salud (GIR-S), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC) Sergas, Universidade da Coruña (UDC), A Coruña, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Tajes</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC) Sergas, Universidade da Coruña (UDC), A Coruña, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Blanco</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC) Sergas, Universidade da Coruña (UDC), A Coruña, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidade da Coruña (UDC), Centro de Investigación de Ciencias Avanzadas (CICA), Grupo de Investigación en Reumatología y Salud (GIR-S), Departamento de Fisioterapia, Medicina y Ciencias Biomédicas, Facultad de Fisioterapia, Campus de Oza, A Coruña, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rego-Pérez</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC) Sergas, Universidade da Coruña (UDC), A Coruña, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">interleukin</Keyword><Keyword MajorTopicYN="N">next-generation sequencing</Keyword><Keyword MajorTopicYN="N">pharmacogenetics</Keyword><Keyword MajorTopicYN="N">tocilizumab</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39346556</ArticleId><ArticleId IdType="pmc">PMC11428153</ArticleId><ArticleId IdType="doi">10.3389/fphar.2024.1426826</ArticleId><ArticleId IdType="pii">1426826</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Al-Kuraishy H. M., Al-Gareeb A. I., Saad H. M., Batiha G. E. (2023). The effect of ramatroban on cytokine and thrombotic storms in Covid-19. Inflammopharmacology 31 (1), 543–545. 10.1007/s10787-022-01114-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-01114-8</ArticleId><ArticleId IdType="pmc">PMC9763788</ArticleId><ArticleId IdType="pubmed">36538271</ArticleId></ArticleIdList></Reference><Reference><Citation>Alomair B. M., Al-Kuraishy H. M., Al-Gareeb A. I., Al-Buhadily A. K., Alexiou A., Papadakis M., et al. (2023). Mixed storm in SARS-CoV-2 infection: a narrative review and new term in the Covid-19 era. Immun. Inflamm. Dis. 11 (4), e838. 10.1002/iid3.838</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.838</ArticleId><ArticleId IdType="pmc">PMC10132185</ArticleId><ArticleId IdType="pubmed">37102645</ArticleId></ArticleIdList></Reference><Reference><Citation>Arman B. Y., Brun J., Hill M. L., Zitzmann N., von Delft A. (2023). An update on SARS-CoV-2 clinical trial results-what we can learn for the next pandemic. Int. J. Mol. Sci. 25 (1), 354. 10.3390/ijms25010354</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25010354</ArticleId><ArticleId IdType="pmc">PMC10779148</ArticleId><ArticleId IdType="pubmed">38203525</ArticleId></ArticleIdList></Reference><Reference><Citation>Attur M., Petrilli C., Adhikari S., Iturrate E., Li X., Tuminello S., et al. (2023). Interleukin-1 receptor antagonist gene (medRxiv.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11175666</ArticleId><ArticleId IdType="pubmed">38871359</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoni A., Penco F., Mollica H., Bocca P., Prigione I., Corcione A., et al. (2022). Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment. J. Allergy Clin. Immunol. 150 (4), 796–805. 10.1016/j.jaci.2022.05.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.05.029</ArticleId><ArticleId IdType="pmc">PMC9272569</ArticleId><ArticleId IdType="pubmed">35835255</ArticleId></ArticleIdList></Reference><Reference><Citation>Boppana T. K., Mittal S., Madan K., Mohan A., Hadda V., Guleria R. (2022). Tocilizumab for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Monaldi Arch. Chest Dis. 92 (4). 10.4081/monaldi.2022.2136</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2022.2136</ArticleId><ArticleId IdType="pubmed">35130679</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D. M., Kim-Schulze S., Huang H. H., Beckmann N. D., Nirenberg S., Wang B., et al. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26 (10), 1636–1643. 10.1038/s41591-020-1051-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello C. A., Simon A., van der Meer J. W. (2012). Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11 (8), 633–652. 10.1038/nrd3800</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3800</ArticleId><ArticleId IdType="pmc">PMC3644509</ArticleId><ArticleId IdType="pubmed">22850787</ArticleId></ArticleIdList></Reference><Reference><Citation>Farid E., Sridharan K., Alsegai O. A., Khawaja S. A., Mansoor E. J., Teraifi N. A., et al. (2021). Utility of inflammatory biomarkers in patients with COVID-19 infections: Bahrain experience. Biomark. Med. 15 (8), 541–549. 10.2217/bmm-2020-0422</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2020-0422</ArticleId><ArticleId IdType="pmc">PMC8120999</ArticleId><ArticleId IdType="pubmed">33988463</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira M. A., Vonk J. M., Baurecht H., Marenholz I., Tian C., Hoffman J. D., et al. (2017). Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nat. Genet. 49 (12), 1752–1757. 10.1038/ng.3985</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3985</ArticleId><ArticleId IdType="pmc">PMC5989923</ArticleId><ArticleId IdType="pubmed">29083406</ArticleId></ArticleIdList></Reference><Reference><Citation>Frodsham A. J., Zhang L., Dumpis U., Taib N. A., Best S., Durham A., et al. (2006). Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc. Natl. Acad. Sci. U. S. A. 103 (24), 9148–9153. 10.1073/pnas.0602800103</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0602800103</ArticleId><ArticleId IdType="pmc">PMC1482581</ArticleId><ArticleId IdType="pubmed">16757563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosn L., Assi R., Evrenoglou T., Buckley B. S., Henschke N., Probyn K., et al. (2023). Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst. Rev. 6 (6), CD013881. 10.1002/14651858.CD013881.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013881.pub2</ArticleId><ArticleId IdType="pmc">PMC10237088</ArticleId><ArticleId IdType="pubmed">37260086</ArticleId></ArticleIdList></Reference><Reference><Citation>Godolphin P. J., Fisher D. J., Berry L. R., Derde L. P. G., Diaz J. V., Gordon A. C., et al. (2022). Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: a network meta-analysis. PLoS One 17 (7), e0270668. 10.1371/journal.pone.0270668</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0270668</ArticleId><ArticleId IdType="pmc">PMC9269978</ArticleId><ArticleId IdType="pubmed">35802687</ArticleId></ArticleIdList></Reference><Reference><Citation>Grk M., Miskovic R., Jeremic I., Basaric M., Dusanovic Pjevic M., Jekic B., et al. (2023). Association of IL10RA, IL10RB, and IL22RA polymorphisms/haplotypes with susceptibility to and clinical manifestations of SLE. Int. J. Mol. Sci. 24 (14), 11292. 10.3390/ijms241411292</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241411292</ArticleId><ArticleId IdType="pmc">PMC10379357</ArticleId><ArticleId IdType="pubmed">37511050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hikami K., Ehara Y., Hasegawa M., Fujimoto M., Matsushita M., Oka T., et al. (2008). Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem. Biophys. Res. Commun. 373 (3), 403–407. 10.1016/j.bbrc.2008.06.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.06.054</ArticleId><ArticleId IdType="pubmed">18588853</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (10223), 497–506. 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamilloux Y., Henry T., Belot A., Viel S., Fauter M., El Jammal T., et al. (2020). Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun. Rev. 19 (7), 102567. 10.1016/j.autrev.2020.102567</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102567</ArticleId><ArticleId IdType="pmc">PMC7196557</ArticleId><ArticleId IdType="pubmed">32376392</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasamatsu T., Saitoh T., Ino R., Gotoh N., Mitsui T., Shimizu H., et al. (2017). Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib. Hematol. Oncol. 35 (4), 711–718. 10.1002/hon.2322</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hon.2322</ArticleId><ArticleId IdType="pubmed">27405747</ArticleId></ArticleIdList></Reference><Reference><Citation>Khazim K., Azulay E. E., Kristal B., Cohen I. (2018). Interleukin 1 gene polymorphism and susceptibility to disease. Immunol. Rev. 281 (1), 40–56. 10.1111/imr.12620</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12620</ArticleId><ArticleId IdType="pubmed">29247999</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Wang D., Wei H., Xu X. (2023). Cytokine storm and translating IL-6 biology into effective treatments for COVID-19. Front. Med. 17 (6), 1080–1095. 10.1007/s11684-023-1044-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-023-1044-4</ArticleId><ArticleId IdType="pubmed">38157195</ArticleId></ArticleIdList></Reference><Reference><Citation>Maculewicz E., Dzitkowska-Zabielska M., Antkowiak B., Antkowiak O., Mastalerz A., Garbacz A., et al. (2022). Association of interleukin genes IL10 and IL10RB with parameters of overweight in military students. Genes (Basel) 13 (2), 291. 10.3390/genes13020291</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13020291</ArticleId><ArticleId IdType="pmc">PMC8871646</ArticleId><ArticleId IdType="pubmed">35205336</ArticleId></ArticleIdList></Reference><Reference><Citation>Napodano C., Carnazzo V., Basile V., Pocino K., Stefanile A., Gallucci S., et al. (2023). NLRP3 inflammasome involvement in heart, liver, and lung diseases-A lesson from cytokine storm syndrome. Int. J. Mol. Sci. 24 (23), 16556. 10.3390/ijms242316556</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242316556</ArticleId><ArticleId IdType="pmc">PMC10706560</ArticleId><ArticleId IdType="pubmed">38068879</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano T., Inui K., Tada M., Sugioka Y., Mamoto K., Wakitani S., et al. (2016). Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol. Int. 36 (3), 349–357. 10.1007/s00296-015-3379-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-015-3379-x</ArticleId><ArticleId IdType="pubmed">26438386</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouyang W., Rutz S., Crellin N. K., Valdez P. A., Hymowitz S. G. (2011). Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29, 71–109. 10.1146/annurev-immunol-031210-101312</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101312</ArticleId><ArticleId IdType="pubmed">21166540</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H. K., Kim D. H., Yun D. H., Ban J. Y. (2013). Association between IL10, IL10RA, and IL10RB SNPs and ischemic stroke with hypertension in Korean population. Mol. Biol. Rep. 40 (2), 1785–1790. 10.1007/s11033-012-2232-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-012-2232-5</ArticleId><ArticleId IdType="pubmed">23096091</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J., She X., Mei H., Zheng H., Fu M., Liang G., et al. (2022). Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis. Aging (Albany NY) 14 (2), 557–571. 10.18632/aging.203834</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.203834</ArticleId><ArticleId IdType="pmc">PMC8833131</ArticleId><ArticleId IdType="pubmed">35038318</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng R., Yang T., Tong Y., Wang J., Zhou H., Yang M., et al. (2023). Efficacy and safety of interleukin-6 receptor antagonists in adult patients admitted to intensive care unit with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Prev. Med. Rep. 34, 102276. 10.1016/j.pmedr.2023.102276</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2023.102276</ArticleId><ArticleId IdType="pmc">PMC10247142</ArticleId><ArticleId IdType="pubmed">37309358</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan A. L., Katz R., Gostin L. O. (2020). The novel coronavirus originating in wuhan, China: challenges for global health governance. JAMA 323 (8), 709–710. 10.1001/jama.2020.1097</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1097</ArticleId><ArticleId IdType="pubmed">31999307</ArticleId></ArticleIdList></Reference><Reference><Citation>Piscoya A., Parra Del Riego A., Cerna-Viacava R., Rocco J., Roman Y. M., Escobedo A. A., et al. (2022). Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: a systematic review and meta-analysis. PLoS One 17 (6), e0269368. 10.1371/journal.pone.0269368</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0269368</ArticleId><ArticleId IdType="pmc">PMC9165853</ArticleId><ArticleId IdType="pubmed">35657993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramírez-Pérez S., De la Cruz-Mosso U., Hernández-Bello J., Martínez-Bonilla G. E., Ramírez-Dueñas M. G., Pereira-Suárez A. L., et al. (2017). High expression of interleukine-1 receptor antagonist in rheumatoid arthritis: association with IL1RN*2/2 genotype. Autoimmunity 50 (8), 468–475. 10.1080/08916934.2017.1412431</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2017.1412431</ArticleId><ArticleId IdType="pubmed">29226727</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., Yang K., Wang W., Jiang L., Song J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46 (5), 846–848. 10.1007/s00134-020-05991-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng F., Han M., Huang Z., Zhang L. (2016). Interleukin 6 receptor inhibitor tocilizumab suppresses cytokine expression, inflammasome activation and phagocytosis in a cell model of sepsis. Pharmazie 71 (11), 636–639. 10.1691/ph.2016.6713</Citation><ArticleIdList><ArticleId IdType="doi">10.1691/ph.2016.6713</ArticleId><ArticleId IdType="pubmed">29441967</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivram H., Hackney J. A., Rosenberger C. M., Teterina A., Qamra A., Onabajo O., et al. (2023). Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19. iScience 26 (9), 107597. 10.1016/j.isci.2023.107597</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107597</ArticleId><ArticleId IdType="pmc">PMC10470387</ArticleId><ArticleId IdType="pubmed">37664617</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., Haq I. (2021). Novel coronavirus disease (COVID-19): origin, transmission through the environment, health effects, and mitigation strategies-a review. Environ. Sustain (Singap) 4 (3), 515–526. 10.1007/s42398-021-00204-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42398-021-00204-7</ArticleId><ArticleId IdType="pmc">PMC8407402</ArticleId><ArticleId IdType="pubmed">36761792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperrin M., Riley R. D., Collins G. S., Martin G. P. (2022). Targeted validation: validating clinical prediction models in their intended population and setting. Diagn Progn. Res. 6 (1), 24. 10.1186/s41512-022-00136-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41512-022-00136-8</ArticleId><ArticleId IdType="pmc">PMC9773429</ArticleId><ArticleId IdType="pubmed">36550534</ArticleId></ArticleIdList></Reference><Reference><Citation>Steri M., Idda M. L., Whalen M. B., Orrù V. (2018). Genetic variants in mRNA untranslated regions. Wiley Interdiscip. Rev. RNA. 9 (4), e1474. 10.1002/wrna.1474</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.1474</ArticleId><ArticleId IdType="pmc">PMC6002891</ArticleId><ArticleId IdType="pubmed">29582564</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg E. W., Harrell F. E. (2016). Prediction models need appropriate internal, internal-external, and external validation. J. Clin. Epidemiol. 69, 245–247. 10.1016/j.jclinepi.2015.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2015.04.005</ArticleId><ArticleId IdType="pmc">PMC5578404</ArticleId><ArticleId IdType="pubmed">25981519</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjernström F., Hellmer G., Nived O., Truedsson L., Sturfelt G. (1999). Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus. Lupus 8 (2), 103–108. 10.1191/096120399678847560</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399678847560</ArticleId><ArticleId IdType="pubmed">10192503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai L. J., Lan J. L., Lin C. Y., Hsiao S. H., Tsai L. M., Tsai J. J. (2006). The different expression patterns of interleukin-1 receptor antagonist in systemic lupus erythematosus. Tissue Antigens 68 (6), 493–501. 10.1111/j.1399-0039.2006.00704.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.2006.00704.x</ArticleId><ArticleId IdType="pubmed">17176440</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaninov N. (2020). In the eye of the COVID-19 cytokine storm. Nat. Rev. Immunol. 20 (5), 277. 10.1038/s41577-020-0305-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0305-6</ArticleId><ArticleId IdType="pmc">PMC7132547</ArticleId><ArticleId IdType="pubmed">32249847</ArticleId></ArticleIdList></Reference><Reference><Citation>Voloudakis G., Vicari J. M., Venkatesh S., Hoffman G. E., Dobrindt K., Zhang W., et al. (2022). A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility. NPJ Genom Med. 7 (1), 52. 10.1038/s41525-022-00324-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41525-022-00324-x</ArticleId><ArticleId IdType="pmc">PMC9441828</ArticleId><ArticleId IdType="pubmed">36064543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J. G., Simpson L. J., Ferreira A. M., Rustagi A., Roque J., Asuni A., et al. (2020). Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight 5 (17), e140289. 10.1172/jci.insight.140289</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140289</ArticleId><ArticleId IdType="pmc">PMC7526438</ArticleId><ArticleId IdType="pubmed">32706339</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S. Y., Koh D. H., Choi M., Ryoo S., Huh K., Yeom J. S., et al. (2022). Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerg. Microbes Infect. 11 (1), 1154–1165. 10.1080/22221751.2022.2059405</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2059405</ArticleId><ArticleId IdType="pmc">PMC9037226</ArticleId><ArticleId IdType="pubmed">35343397</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Qin L., Zhang P., Li K., Liang L., Sun J., et al. (2020). Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight 5 (13), e139834. 10.1172/jci.insight.139834</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.139834</ArticleId><ArticleId IdType="pmc">PMC7406242</ArticleId><ArticleId IdType="pubmed">32501293</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>